Status:
COMPLETED
A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
Lead Sponsor:
Pfizer
Conditions:
COVID-19
Eligibility:
All Genders
Brief Summary
The purpose of this study is to learn about: * effects of living with COVID-19 and * how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients ...
Eligibility Criteria
Inclusion
- Cohort 1:
- Patients of all ages
- Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021
- Cases of patients registered in the databases
Exclusion
- Patients without COVID-19 diagnosis
- Cohort 2:
- Inclusion Criteria:
- ≥12 years of age
- Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022
Key Trial Info
Start Date :
November 7 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2025
Estimated Enrollment :
8252912 Patients enrolled
Trial Details
Trial ID
NCT06085924
Start Date
November 7 2023
End Date
February 28 2025
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Taiwan
Taipei, Taiwan